-0.014 (-2.78%)
Range 0.470 - 0.499   (6.17%)
Open 0.490
Previous Close 0.504
Buy Price 0.475
Buy Volume 18
Sell Price 0.479
Sell Volume 9
Volume 4,343,628
Value -
Measurement Type Value
EPS (USD) -0.096
Trailing EPS (USD) -0.064
NAV (USD) 0.015
Cash In Hand (USD) 0.108
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 33.846
Price / Cash In Hand 4.687
Issued & Paid-up Shares 62,678,600
Treasury Shares -
Market Cap (M) 31.609
Par Value (USD) n.a.
Beta - 75 Days 0.465
R-Squared - 75 Days(%) 0.82
Beta - 500 Days 0.644
R-Squared - 500 Days(%) 2.49
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 14 Aug 2020 04:00.
Data powered by
View All Events


Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. The Company�s pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The development priorities in oncology are the completion of Phase 3 trials with perifosine in colorectal cancer (CRC) and in multiple myeloma (MM), as well as the further advancement of AEZS-108, for which it has completed a Phase 2 trial in advanced endometrial and advanced ovarian cancer. Its pipeline also encompasses other earlier-stage programs in oncology. AEZS-112, which is an oral anticancer agent, which includes three mechanisms of action (tubulin, topoisomerase II and angiogenesis inhibition) has completed a Phase 1 trial in advanced solid tumors and lymphoma.

Loading Chart...